Drug companies are making billions from a new class of in-demand weight-loss treatments. But the prices are not what they seem.Drug companies are making billions from a new class of in-demand weight-loss treatments. But the prices are not what they seem.Read MoreSemaglutide (Drug), Ozempic (Drug), Tirzepatide, Drugs (Pharmaceuticals), Prices (Fares, Fees and Rates), Obesity, Health Insurance and Managed Care, Eli Lilly and Company, Novo Nordisk A/S, American Enterprise Institute for Public Policy ResearchNYT > Health